Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

116.30 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 116.30
Bid (Size) 116.33 (2)
Ask (Size) 116.37 (25)
Prev. Close 116.30
Today's Range 116.30 - 116.30
52wk Range 90.56 - 116.27
Shares Outstanding 228,994,568
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rule 17(e) Announcement - Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Peering Into Horizon Therapeutics's Recent Short Interest
Via Benzinga

Performance

YTD
+2.47%
+2.47%
1 Month
N/A
N/A
3 Month
+0.68%
+0.68%
6 Month
+16.69%
+16.69%
1 Year
+18.10%
+18.10%

More News

Read More
Horizon Therapeutics PLC (NASDAQ: HZNP) Climbs to New 52-Week High
Via Investor Brand Network
Rule 17(d) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Here's How Much $100 Invested In Horizon Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics PLC (NASDAQ: HZNP) Climbs to New 52-Week High
Via Investor Brand Network
How Is The Market Feeling About Horizon Therapeutics?
Via Benzinga
$1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
From Horizon Therapeutics plc
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics PLC (NASDAQ: HZNP) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
From Horizon Therapeutics plc
Via Business Wire
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
From Horizon Therapeutics plc
Via Business Wire
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
3 Growth Stocks to Buy in September
Via MarketBeat
Topics Economy
Exposures Economy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.